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Abstract - The main purpose of this study is to
analyzing the financial performance and wealth
maximization of acquiring companies and evaluates
their financial and operating performance pre and post
period of the merger. To conduct a constant research
and arrive at an actual conclusion, we focus our research
to only Indian Pharmaceutical companies. The idea of
this article is to explore various views of Merger and
Acquisitions related to the Indian Pharmaceutical sector
in particular. To explain the impact of M&A on the
companies
of
Sun
Pharmaceuticals
and
Ranbaxy Laboratories Torrent Pharma and Elder
Pharma has been taken into account as a case study of
my study. With the help of profitability and solvency
ratios like ROTA, ROCE, Net Profit Margin, and DebtEquity Ratio, ROE, Gross Profit Margin It focus the
financial condition of the concern during the pre and
post merger period .This study also evaluates the
independent Paired t-test by the help of SPSS for testing
the statistical reliability of the firms and this test is used
both for the ratio analysis and to understand the impact
of Merger and Acquisitions. All these results are mainly
based on the data collected from the company’s
financial statements.

different opportunities with the route of merger or
acquisition. Internal Expansion can take place with
the introduction of new techniques, setting new
ideas related to products and services and
increasing the overall efficiency and effectiveness
of the organization. Through this internal
expansion takes place at a gradually but in
competitive era a completely new shape of external
expansion has been taken into existence which
takes place in the way of takeovers and
amalgamations, mergers, acquisitions. Now a day
business world, these procedures are apply many
fields of industries which including FMCG
products, telecommunications and information
technology pharmaceuticals, hospitality, and many
more.
In this context we provide an overview of the
basic comparison between the finely varying terms
like merger, amalgamation, acquisitions and joint
ventures. Also we give a brief idea of the laws
associated with the areas of M&A activities. We
glance at the recent prominent mergers in the
country followed by a case study on the horizontal
merger between the Sun Pharmaceuticals and
Ranbaxy Laboratories and Torrent Pharma and
Elder Pharma in the year 2014 showing the impacts
of merger and acquisition.

Keywords - Impact of M&A in Indian Pharmaceutical
sector, Analyses and effects of merger in Indian
Pharmaceutical sector.

INTRODUCTION
Currently India is the third largest in the world
pharmaceutical market. M&A is one of the major
aspects in present corporate industry. With the
objective of maximizing shareholder value and
profit maximization, companies keep analyzing

REVIEW OF LITERATURE


Lubatkin [2009] analyzed the results of study
that directly or indirectly indicate to the
question whether mergers give benefits to the
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acquiring firms and came up with the result
that the acquiring firms have a chance of being
benefited due to diversified operations
monetary and technical activities.




RESEARCH HYPOTHESIS:H0: Merger and Acquisition have no impact on
operating performance.
H1: Merger and Acquisition have positive impact
on operating performances.

A.T. Kearney [2010] states that when a
pharmaceutical company functioning at a large
level mutually with other pharmaceutical
company, it conclude that in a consumer
benefit with an expanded product.

H0: Merger and Acquisition have no impact on
shareholder’s wealth.
H1: Merger and Acquisition have positive impact
on shareholder’s wealth.

VidhishVyasetal (2012) in this article made an
attempt to study the more variables of mergers
and acquisitions in Indian pharmaceutical
industry. They suggested that one form of
gaining efficiency in M&A is the combined
effect of organizational management if the
managers of the acquiring company possess
superior managerial capabilities.

METHODOLOGY:Data are collected from various sources for this
study .

From the above study, it is conclude that here
there is no conclusive proof about the basic impact
of M&A on the firm‘s operating and financial
activities. This research is focus to determine the
impact of M&A on the post-merger performance
and provide the implication on value of the
organization.
RELEVANCE OF THE STUDY: This study will
carry on knowing the effects of merger and
amalgamation in shareholder value and profit of
the pharmaceutical sectors. The main purpose of
the study what is the main impact of mergers and
acquisitions on the operating and financial
performance based activities and shareholder
wealth of both the firms.



The
required data are taken through
published financial and annual reports of the
selected Company website.



For the purpose of study we taken 7 years
data, 3 years for pre-merger period and 3
years for post-merger period.2014 is taken as
base year as it the year of merger.



The various financial techniques such as
ratio analysis, trend analysis is being used.
The profiles of both acquiring and acquired
firms at the time of merger/acquisition have
been collected from annual reports,
newspaper clippings, websites etc.
S. N.

Bidder firm

Sun
Merger 1 pharmaceutical
Ltd.
Torrent
Merger 2 pharmaceutical
Ltd.

OBJECTIVE OF THE STUDY:-

Target firm

Year

Ranbaxy
pharmaceutical
Ltd.

2014

Elder pharmac
eutical Ltd.

2014

ANALYSIS AND INTERPRETATION:-

The two main aims of this study are mentioned
below-

For my research study I have taken Return on
capital employed, Gross Profit Margin, Total debtequity ratios Operating Profit Margin, Net profit
margin, for evaluate the Operating performance of
company and Earning per share, Return on net
worth and Earning Retention Ratio for evaluate
the Shareholder’s Wealth of the company.

1. To measure the impact of mergers and
acquisitions on the operating and financial
performance of the firm.
2. To analyze the effect of pre and post merger
and acquisition on shareholder’s value in
pharmaceutical sectors.
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of 0.016 and 0.004 which is less than 0.05%, so it
is significant.So, H0 (null hypotheses) is rejected
leading to the acceptance of H1 (alternate
hypotheses).So it will show that no significant
impact between pre and post-merger period . In
the above analysis shows that after merger the
Operating Performance will go down in three ratios
but on the other hand Debt-Equity ratio and gross
profit ratio will increase which shows that the of
Ranboxy is have a mixed impact on Sun pharma
with regard to operating performance of the bidder
firm.

Table 1: Analysis of financial ratios of Sun
Pharma for Operating Performance
Sun Pharma
Operating
Profit Margin
Gross Profit
Margin
Net Profit
Margin
Return on
Capital
employed
Debt-equity
Ratio

Mean

S.D

Pre
Post
Pre
Post
Pre
Post
Pre

31.00
29.84
25.83
46.57
31.00
18.24
23.60

17.25
2.06
2.06
2.80
17.23
3.47
3.20

Post

20.55

1.52

Pre

0.023

0.15

Post

0.256

0.04

t-value

pvalue

0.105

0.9

-7.937 0.016
1.277

0.33

1.359

0.30

-16.059 0.004

To evaluate the financial difference we can use
financial ratios before and after merger, paired
t-test use with the help of SPSS.

(Source:-Compilation from financial state of data
retrieves Moneycontrol.com by SPSS)

The above analysis would show in table 1. The
Net profit margin, Operating profit margin, ROCE
ratio the p-value is more than 0.05 percent, it can
be find that there is no significant difference in
these ratios before and after merger. For Gross
Profit Margin and Debt-Equity Ratios the p value
was less than 0.05 percent so it can be ascertained
that there is a difference before and after merger.
So the Operating Performance will go

For my study, I have used Paired ‘t’ test for
data analysis with the help of SPSS Packages.
It will show that the mean value of the
operating profit margin is decreased from 31% to
29.84% post merger period with t-value 0.105
which is statistically significant at 0.05%
significance level as the critical p-value is 0.9
which is above 0.05,so it is insignificant. Same as
the mean value of net profit margin and ROCE has
significantly decreased from 31% to 18.24% and
23.60% to 20.55% during post merger period as
compared to pre-merger period with t-value of
1.277,1.359 respectively and P value of 0.30 and
0.33 which is above than 0.05%, so it is
insignificant. The decrease in all these three ratios
signifies that the operating performance has
significantly gone down in post-merger.
Consequently H0 (Null Hypotheses) is accepted
which shows that there are no significant
differences between pre and post-merger operating
performance in terms of operating profit margin,
net profit margin and ROCE of Sun Pharma . On
the other hand, the mean value of Gross profit
margin and Debt-Equity Ratios has significantly
increased to 25.83% to 46.57% and 0.02% to
0.25% during post merger period as compared to
pre-merger period with t-value of -7.937 and 16.059 respectively and in the other hand P value

down during pre and post-merger period but the
debt-Equity will more stronger in after merger
period.
Table 2:-Analysis of financial ratios of Sun
Pharm. for Shareholder’s wealth
Sun Pharma
Return on
Net worth
Earnings
Per
Share(EPS)
Earning
Retention
Ratio

Mean

S.D

Pre
Post
Pre

23.50
16.84
53.53

2.36
2.72
11.87

Post

89.14

6.24

Pre

39.47

4.89

Post

89.15

6.25

t-value

pvalue

3.413

0.076

-4.464

0.04

-24.085 0.002

(Source:-Compilation from financial state of data
retrieves Moneycontrol.com by SPSS)

Shareholder’s wealth of pre and post-merger period
will evaluated on the basis of key ratios. Here
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Return on Net worth, Earnings Per Share (EPS),
Earning Retention Ratio are indicates Performance
Indicators.

It would be shown that the mean value of the
operating profit margin and ROCE has decreased
from 32.45% to 6.10%,35.53% to 28.77% and post
merger with t-value 3.10 and 0.424 which is
statistically significant at 0.05% significance level
as the critical p-value is 0.090 and 0.713 which is
above 0.05,so it is insignificant. . On the other
hand, the mean value of Gross profit margin, Net
profit margin and Debt-Equity ratio has
significantly increased to 22.56% to 27.46% ,
4.13% to 22.85%,0.53% to 0.60% during post
merger period as compared to pre-merger period
with t-value of respectively and P value of
0.685,0.65 and 0.289 which is above than 0.05%,
so it is insignificant. The increasing trends of all
these three ratios shows
that the operating
performance has significantly gone up in postmerger. Consequently H0 is accepted which
evaluates us to ascertain that there are no
significant differences between pre and postmerger operating performance in terms of Gross
profit margin, Net profit margin, Debt-Equity
Ratios of Tarrent Pharma. In the above analysis
shows that after merger the Operating Performance
will go up which will a favorable effect to the
Tarrent Pharma the bidder firm.

For my study, I have used Paired‘t’ test for data
analysis with the help of SPSS Packages.
It would be evaluated that the mean value of
the Return on net worth ratios has decreased from
23.50% to 16.84% post merger with t-value 3.413
which is statistically insignificant at 0.05%
significance level as the critical p-value is 0. 0.076
which is above 0.05, so it is insignificant. The
mean value of EPS and Earning Retention Ratio
has significantly increased from 53.53% to 89.14%
and 39.47% to 89.15% during post merger period
as compared to pre-merger period with t-value of 4.464 and -24.085 and P value of 0.04,0.002
respectively. The increase in all these two ratios
signifies that the shareholder’s wealth has
significantly gone up in post-merger. Consequently
H1 is accepted which will show that there are
significant differences between pre and postmerger shareholder’s wealth in terms of Return on
net worth margin, EPS,Earning Retention Ratios
of Sun Pharma. So the Shareholder’s Wealth will
go up during pre and post-merger period.

Table No-4:-Analysis of financial ratios of Torrent
Pharma for Shareholder’s wealth

Analysis of financial ratios of Torrent Pharma
for Operating Performance

Operating
Profit Margin
Gross Profit
Margin
Net Profit
Margin
Return on
Capital
employed
Debt-equity
Ratio

Mean

S.D

t-value

pvalue

Pre
Post
Pre
Post
Pre
Post
Pre

32.45
6.10
22.56
27.46
4.13
22.85
35.53

Post

28.77

13.94
3.10 0.090
0.85
4.56
-0.470 0.685
14.87
0.74
-3.736 0.65
7.96
14.57
0.424 0.713
18.01

Pre
Post

0.53
0.60

0.11
-1.429 0.289
0.20

Mean

S.D

Pre

30.93

4.38

Post

31.47

18.06

Pre

28.03

13.19

Post

226.07

58.21

Pre

13.85

2.19

Post

66.70

3.90

Return on
Net worth

Table 3:- Analysis of financial ratios of Torrent
Pharma for Operating Performance
Torrent Pharma

Torrent Pharma

Earnings
Per
Share(EPS)
Earning
Retention
Ratio

t-value

pvalue

-0.046

0.967

-7.181

0.019

-12.278 0.052

The Shareholder’s wealth will evaluated on the
basis of key ratios. Here Earning RetentionRatio
,Return on Net worth, Earnings Per Share (EPS)
are indicates Performance Indicators.
For my study, I have used Paired’ test for data
analysis with the help of SPSS Packages.

(Source:-Compilation from financial state of data
retrieves Moneycontrol.com by SPSS)
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It would be shown that the mean value of the
Return on net worth ratios has increased from
30.93%to 31.47% post merger with t-value -0.406
which is statistically insignificant at 0.05%
significance level as the critical p-value is 0.967
which is above 0.05, so it is insignificant. The
mean value of EPS has significantly increased
from 28.03% to 226.07% during post merger
period as compared to pre-merger period with tvalue of -7.181 and P value of 0.019.The increase
in all these two ratios signifies that the
shareholder’s wealth has significantly gone
improve in post-merger. Consequently H1 is
accepted which will evaluates that there are
significant differences between pre and postmerger shareholder’s wealth in forms of Return on
net worth margin, EPS ratios of IOCL and H0 is
accepted in Return on Net worth

REFERENCES

To evaluate the financial difference in the
financial ratios before and after merger, paired
t-test is use with the help of SPSS.
This analysis presented in table 4.The return on
net worth is more than 0.0 5 percent, it can be
concluded that there is no significant difference in
these ratios before and after merger. For Earning
Retention Ratio , Earnings Per Share (EPS) the p
value was less than 0.05 percent so it can be
concluded that there is a significant difference
before and after merger. So the shareholder wealth
will go up during pre and post-merger period of
Tarrent Pharma.

[1]

Srivastava, A. (2016). Opportunities and
threats of mega merger: A case study of sun
pharmaceuticals and Ranbaxy laboratories.
International Journal of Commerce and
Management Research, 2, 112-115.

[2]

Kamra, K., & Gupta. M. (2016).
Comprehensive
Research
on
the
Performance of the Acquiring firms Pre and
Post-Acquisition in the Pharmaceutical
Industry. IOSR Journal of Economics and
Finance (IOSR-JEF), 7(1), 10-17.

[3]

Shah, H. (2018). Mergers and Acquisitions
in the Indian Pharmaceutical Sector: Trends,
Sample Study, and Financial Analysis of Pre
and Post Merge. International Journal of
Science, Engineering and Management
(IJSEM), 3(2), 55-68.

[4]

Duggal, N. (2015). Post Merger Performance
of Acquiring Firms: A Case Study on Indian
Pharmaceutical
Industry.
International
Journal of Research in Management &
Business Studies (IJRMBS), 2(3), 24-28.

[5]

Ashfaq. K. (2014). Investigating the Impact
of Merger & Acquisition on Post Merger
Financial Performance (Relative & Absolute)
of Companies. Research Journal of Finance
and Accounting, 5(13), 88-101.

[6]

Venkateswarlu, K. (2018). Mergers and
Acquisitions: Boom in the Indian Pharma
Industry. UPI Journal of Business
Management and Computer Applications,
1(1), 26-30.

[7]

Keong. C. (2007). Performance of Mergers
and Acquisitions in the Pharmaceutical
Industry:A
comparative
prospective.
EkremTatoglu
Multinational
Business
Review,15(2), 41-61.

[8]

Annualports of sunpharma, Ranbaxy, torrent
pharma and elder pharma.

CONCLUSION
In this study, I am taken 7 year data of pre and
post-merger period of two pharmaceutical sectors
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taken base year. As a result of analyses made,
before merger the operating performance of Sun
Pharma is good but after merger is go up and the
shareholder’s wealth is also go up after merger
period .On the other hand, before merger the
operating performance of Tarrent Pharma is good
but after merger is go up and the shareholder’s
wealth is improved after merger period.
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